There is one clinical trial.
This clinical trial is examining the role of genetic polymorphism on the effect of clopidogrel (with or without aspirin) on platelet response in persons at high-risk for myocardial infarction or stroke due to family history of early-onset coronary artery disease.
Platelet Aggregation Platelet Transcriptome Coronary Artery Disease Coronary Artery Disease The main goal of this study is to explore the impact of the PEAR1 genetic variant (rs12041331) on responsiveness to clopidogrel.
Description: ADP-induced platelet aggregation will be measured using impedance aggregometry in whole blood before and after 1-week of clopidogrel. The difference between the baseline and after clopidogrel therapy will be determined. Higher impedance represent higher platelet aggregation.
Measure: Difference in ADP-induced Platelet Aggregation Time: at baseline and at 1 weekDescription: Arachidonic Acid-induced platelet aggregation will be measured using impedance aggregometry in whole blood before and after 1-week of clopidogrel. The difference between the baseline and after clopidogrel therapy will be determined
Measure: Difference in Arachidonic Acid-induced Platelet Aggregation Time: At baseline and after 1-weekDescription: Collagen-induced platelet aggregation will be measured using impedance aggregometry in whole blood before and after 1-week of clopidogrel. The difference between the baseline and after clopidogrel therapy will be determined
Measure: Difference in Collagen-induced Platelet Aggregation Time: At Baseline and at 1 weekDescription: Platelet transcriptome will be examined before and after 1 week of therapy with clopidogrel and differences will be determined
Measure: Changes in Platelet Transcriptome With Clopidogrel Time: At baseline and at 1 week